Announcement of Availability to Investigators of Mosunetuzumab (NSC 833090)

March 02, 2022

The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using mosunetuzumab, a bispecific antibody that targets CD20 and CD3, which is being developed by CTEP as an anticancer agent in collaboration with Genentech, Inc. CTEP will also consider requests to supply mosunetuzumab for nonclinical studies. All clinical and nonclinical researchers possessing an interest in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical data (see “Components of a Competitive Letter of Intent” at

All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.

Questions may be addressed to Dr. Elad Sharon (, Medical Officer, Investigational Drug Branch, CTEP.

For more information please see related documents below.